Blood Diseases Hospital
Blood Diseases Hospital
Tianjin, Tianjin Municipality, China12 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Not applicable | 2026-08-10 | NCT07495631 | |
| Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia | DNMT3A Gene Mutation | Recruiting | Phase 1 | 2026-08-10 | NCT07188740 | |
| MRD-positive AML Clinical Study | Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Not applicable | 2026-08-10 | NCT07131059 | |
| Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML | acute myeloid leukemia | Recruiting | Not applicable | 2026-08-07 | NCT07490288 | |
| Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 | acute myeloid leukemia | Recruiting | Phase 3 | 2026-08-07 | NCT06744504 | |
| Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL | Ph+ ALL | Recruiting | Not applicable | 2026-07-23 | NCT07493161 | |
| ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Not applicable | 2026-05-13 | NCT07454226 | |
| HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML | acute myeloid leukemia | Active, not recruiting | Phase 2 | 2026-05-13 | NCT06744556 | |
| Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-05-13 | NCT06635681 | |
| Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML | acute myeloid leukemia | Recruiting | Phase 1 / Phase 2 | 2026-05-13 | NCT06611839 | |
| The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation | acute myeloid leukemia | Recruiting | Phase 1 / Phase 2 | 2026-05-13 | NCT06561880 | |
| Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML | CML,Blast Phase | Recruiting | Phase 1 / Phase 2 | 2025-05-30 | NCT06757855 |